Ladies and gentlemen, thank you for standing by. My name is Brent, and I will be your conference operator today. At this time, I would like to welcome everyone to the Omnicell Third Quarter 2022 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question at that time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again, press star one. Thank you. It is now my pleasure to turn today's call over to Kathleen Nemeth, Senior Vice President of Investor Relations. Please go ahead. Good morning, and welcome to the Omnicell Third Quarter Financial Results Conference Call. On the call with me today are Randall Lipps, Omnicell Chairman, President, CEO, and Founder, Scott Seidelmann, Executive Vice President and Chief Commercial Officer, and Peter Kuipers, Executive Vice President and Chief Financial Officer. This call will contain forward-looking statements, including statements related to financial projections or other statements regarding Omnicell's plans, objectives, expectations, targets, expense management, or outlook that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied. For a more detailed description of the risks that impact these forward-looking statements, please refer to the information in our press release issued today in the Omnicell annual report on Form 10-K filed with the SEC on February 25, 2022, and in other more recent reports filed with the SEC. Please be aware that you should not place undue reliance on any forward-looking statements made today. All forward-looking statements speak only as of the date hereof or the date specified on the call. Except as required by law, we do not assume any obligation to update or otherwise release publicly any revisions to our forward-looking statements. Our results were released this morning and are posted in the investor relations section of our website at ir.omnicell.com. Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. Reconciliation of these non-GAAP measures to the most comparable GAAP financial measures are included in our financial results press release posted in the investor relations section of our website. With respect to forward-looking non-GAAP measures, such as guidance and targets, we do not provide a reconciliation of forward-looking non-GAAP measures to the comparable GAAP measures on a forward-looking basis, as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort. With that, I will turn the call over to Randall. Thank you, Kathleen. Good morning, and thank you for joining us today. This quarter, we continued to advance our strategy to transform the pharmacy care delivery model and deliver mission-critical medication management solutions to our customers. As I said at our recent Investor Day, I started this company 30 years ago to improve medication management and enable medical caregivers to spend more time with their patients. We continue to innovate each day to further this objective, as well as to achieve our mission to be the clinician's most trusted partner. Our go-forward strategy is not only to continue to advance these important objectives, but also to deliver on the tremendous growth we see ahead of us as we transition our business to an as-a-service model. It is clear to us that our strategy is working as the demand for our advanced services, including retail SaaS solutions, remains strong. Advanced services are Omnicell's future, and we are especially encouraged by the strong results we are seeing for these solutions. We continue to focus on the long-term value we believe we can create by delivering cloud-based platform solutions designed to enable SaaS and tech-enabled pharmacy operations across the entire continuum of care. With that said, in the near term, we are seeing significant headwinds in our point of care products. The economic environment, including its effect on our health system customers, shifted rapidly toward the end of third quarter. This has caused many health systems to implement capital budget freezes and additional budget approval processes, which is resulting in elongated sales cycles. At the same time, ongoing health system labor constraints have continued to increase, which has resulted in a higher than typical number of customers requesting to temporarily defer point of care implementations. These factors have adversely affected bookings and revenue in our point of care business, and we are updating our overall bookings and revenue outlook for the year accordingly. I do want to point out that despite the current environment, we are continuing to see major implementations move forward. We continue to believe our customers recognize the need for our point of care products to meet compliance. Like many other companies across industries, we are navigating a dynamic macroeconomic environment. We will continue to respond to this changing environment, including by implementing appropriate actions on expenses where needed, to take what we believe is a prudent and disciplined approach to managing our business through this period. I'll speak more about these actions in a minute. Let's walk through the third quarter financial results. Third quarter revenue of $348 million was below our guidance range, driven primarily by customer requests to reschedule delivery and implementation of our point of care products. GAAP net income for the third quarter of 2022 was $17 million or $0.37 per diluted share. Non-GAAP net income for the third quarter of 2022 was $45 million or $1 per diluted share. This was in line with our guidance due to strong expense management, as well as reductions in performance-based compensation expense. Non-GAAP EBITDA for the third quarter of 2022 was $61 million. As I mentioned, despite headwinds in point of care, our advanced services, including our EnlivenHealth products and solutions, continue to see robust demand. One example of this demand is the fact that in the third quarter, we installed a record number of CPDS, or that's our XR2 robot as-a-service installations. We are also pleased with the momentum we are seeing in Omnicell One and the strong demand for our IV compounding service. During the third quarter, EnlivenHealth closed a deal with a major Northeast-based pharmacy chain that contracted for two key digital solutions. EnlivenHealth is expected to exit 2022 with an approximate annual revenue run rate or ARR of $90 million as our retail customers appear to increasingly turn to EnlivenHealth for our uniquely positioned SaaS offerings. As well, we now have 152 of the top 300 U.S. health systems under long-term sole source contracts. Many recent long-term sole source wins have been competitive conversions. This was the case for one of our two new long-term sole source customers, with the other being an existing Omnicell customer that expanded its relationship with us. Whether a competitive conversion or a current customer, we believe health systems are choosing to enter into long-term sole source contracts with Omnicell due to our strong positioning with our advanced services offerings. Scott will provide more color on this growth shortly, but I wanted to acknowledge that our strong presence across the U.S. health system is a testament to our 30 years of hard work by Omnicell employees. We find that the breadth and depth of our channel, our comprehensive portfolio of solutions, and our singular focus on the pharmacy continue to be important points of competitive differentiation for the company. We believe that we are uniquely positioned to capitalize on the growth opportunities ahead, and that we're just getting started. We are facing headwinds and operating in a difficult environment. As I said on our last call, Omnicell has been through many different market cycles in the past 30 years. We have navigated each of those cycles and evolved our business to ensure we meet our customers' needs, and we will continue to do so. On that note, I want to address how we intend to navigate the headwinds we are seeing. We plan to take actions to significantly reduce expenses with a review of all areas of our cost structure underway. We intend and believe we have the ability to adjust our spending to align with revised bookings and revenue levels. At the same time, we plan to continue to invest in our advanced services. We believe they are Omnicell's future and that our continued investment in R&D and our innovation roadmap will enable us to continue to transform our business and support our growth agenda. Near term, we anticipate operating against a challenging backdrop, and we have revised our outlook for the year, taking this expectation into account. That said, we continue to be confident in our strategy, and we believe Omnicell is well positioned to enable the digital transformation of the entire medication management continuum. Our healthcare system customers recognize the value Omnicell provides, and we look forward to delivering long-term value to all of our stakeholders. With that, let me turn it over to Scott for some details on the quarter. Thank you, Randall. As Randall noted, we saw significant headwinds, primarily in our point of care products and solutions this quarter. Hospitals and health systems are under financial pressure, experiencing labor constraints, in some instances resulting in CapEx budget freezes and/or additional budget approval processes resulting in elongated sales cycles. Also, in some cases, we have seen pauses in point of care implementations due to availability of health system labor or hospital construction delays. We are also now well over 50% through the XT upgrade cycle. We are currently operating in a difficult environment, particularly with respect to point of care. However, it is important to understand that we strongly believe our strategy to transform our business to an as a service model is working. How do we know? Let's look at a few of the key indicators we are tracking to gauge our success. First, we are seeing many of our advanced services customers achieving real ROI with these solutions. Whether it's through improved patient care, reduced labor expense, better compliance, and/or improved financial performance, our customers are relying on us to partner with them to address their most pressing medication management challenges across the continuum of care. As a result, we are seeing increasing referenceability for our services with customers proactively sharing their successes with other health systems. We are also seeing strong demand in the market, and our pipeline for these services appears to be growing faster than the market. Also this quarter, we saw record revenue for our Central Pharmacy Dispensing Service. Lastly, as I will discuss further in a moment, our advanced services portfolio continues to differentiate Omnicell with large health systems. For all of these reasons, we intend to accelerate our transition to advanced services, and we are continuing to invest in our growth agenda. One example of what we believe is smart continued investment in our advanced services is our recently launched specialty pharmacy service that can help provide hospital systems with an additional, potentially significant source of revenue to help ease some of the financial pressures that they are facing. We also believe that in the future, our transition to advanced services, which comes with projected predictable recurring revenue, will ease the point of care replacement cycle challenge we are currently experiencing. Next, I'll touch on a few of our recent customer highlights. At Investor Day, I spoke about our vision to transform health care by optimizing medication management within each setting of care with the patient at the center. We believe that this vision is resonating strongly with customers. Randall spoke briefly about this in his remarks, and we are really excited about the long-term sole source customers we have added recently as we continue to build strong partnerships among top 300 health systems through these agreements. To that end, we are excited to announce that a Virginia-based health system signed a 5-year sole source agreement for Omnicell Central Pharmacy and point of care dispensing solutions, inventory optimization services, and cloud-hosted medication management platform. This customer signed the agreement after successfully adopting Omnicell's IV Compounding Service. This win of a top 300 health system customer was a competitive conversion that we understand was won due to our expertise and our commitment to investment in and focus on next generation medication management. We are also excited to announce a new 10-year long-term sole source agreement signed with an Indiana-based health system. This customer was also an IV customer that is now implementing both XT automated dispensing systems and Omnicell One, our SaaS advanced service that delivers inventory optimization capabilities. With the addition of Specialty Pharmacy Services to our portfolio, we are engaging our customers more strategically. Our Specialty Pharmacy Services team can work with customers to identify how the addition of an in-house specialty pharmacy will lead to better patient care and potentially significantly improve financial performance. Specialty pharmacy is a significant part of medication management, and our Specialty Pharmacy Service is a key part of our portfolio. We signed 2 significant customers this quarter, and our pipeline continues to grow. This quarter, a long-time Omnicell customer in the South adopted additional advanced service offerings for inventory optimization and Central Pharmacy Dispensing Service to improve visibility and accelerate time to value realization for these solutions. We also hosted over 280 health systems for our fall Illuminate LIVE event, which included the formal launch of our Specialty Pharmacy Services offering that further expands our portfolio of advanced services and other exciting solution updates. Event participants appeared very interested to hear how Temple University Hospital, a Specialty Pharmacy Services customer, is achieving significant financial outcomes through their in-house specialty pharmacy operations. Also within our advanced services portfolio, EnlivenHealth has been performing very well. EnlivenHealth is helping pharmacies streamline and automate their patient engagement and clinical and financial workflows. This frees up critical time for pharmacists, allowing them to practice at the top of their license and provide high-value clinical services that improve patient health outcomes and strengthen bottom-line pharmacy business results. As Randall mentioned earlier, we are excited about the new deal we closed with a major Northeast-based pharmacy chain that contracted for two key digital solutions. We believe our strong execution will continue to help retail pharmacies overcome current challenges to deliver better care and increase profit. This is currently a difficult business environment, and we are disappointed in these results. However, we are pleased that we added two new long-term sole source customers and that we continue to see strong demand and make solid progress with our advanced services, including our EnlivenHealth solutions. While this near-term period may be difficult, we are confident in our transition to an as-a-service model and excited to work closely with our customers to transform healthcare for the better. I will now turn it over to Peter. Thank you, Scott. This was a very challenging quarter, with the business environment shifting rapidly towards the end of the quarter. As Randall noted, we are seeing a high level of customer requests to postpone point-of-care installations. Hurricane Ian also occurred late in the quarter, which delayed multiple customer implementations. Both of these factors negatively impacted our revenue. In addition, we're seeing an increasing number of health systems implement CapEx budget freezes or additional CapEx approval requirements, which have resulted in lower expected bookings for the full year. It is important to note that the vast majority of the decrease in expected full year 2022 bookings is in point-of-care products. Demand for our advanced services remains robust. While revenue was modestly impacted in the third quarter, I'm pleased that strong expense management as well as lower performance-based compensation expense enabled us to deliver non-GAAP EBITDA and non-GAAP EPS within our guided ranges. Omnicell employees across the company continue to put our customers first, and I'm pleased with our team's diligent expense management during the quarter, as well as the solid execution that our more than 4,100 Omnicell team members continue to consistently deliver in a macroeconomic environment that remains challenging. Turning now to a review of our third quarter results. Our third quarter 2022 GAAP and non-GAAP revenues were a record $348 million. Our non-GAAP revenues increased $17 million or 5% over the prior quarter and were up 17% over the third quarter of 2021. The year-over-year revenue increase reflects strong demand for Omnicell's mission-critical medication management automation solutions, as well as the contribution of revenue from recent acquisitions. Total revenue in the quarter was below our guidance range, primarily due to customer timing delays, including delays from health system labor availability, and a small portion due to the impact of Hurricane Ian and FX headwinds. Our third quarter 2022 organic GAAP and non-GAAP revenues increased 11% year over year. In addition, the acquisitions of FDS Amplicare, ReCept, now referred to as Specialty Pharmacy Services, and MarkeTouch Media are performing well, and we expect these recent acquisitions to support our long-term growth objectives. Non-GAAP gross margin for the third quarter of 2022 was 47.5%, a decrease of 200 basis points from the prior quarter. This decrease was primarily due to the product and customer mix of implementations during the quarter, as well as higher employee-related costs due to higher headcount and our annual merit increase, which became effective on July 1. Our third quarter 2022 GAAP earnings per share were $0.37 per share compared to $0.20 per share in the second quarter of 2022, and $0.61 per share in the third quarter of 2021. As a reminder, third quarter 2021 GAAP EPS and non-GAAP EPS included a stock excess tax benefit of $0.15 per share compared to $0.03 per share in the third quarter of 2022. A full reconciliation of our GAAP to non-GAAP results is included in the third quarter 2022 financial results press release posted in the investor relations section of our website. Our third quarter 2022 non-GAAP earnings per share was $1 per share, meeting the high end of our guided range compared to $0.84 per share in the previous quarter and $1.08 per share in the same period last year. We delivered non-GAAP EBITDA of $61 million in the third quarter of 2022 compared to non-GAAP EBITDA of $56 million in the previous quarter and $66 million in the same quarter last year. Despite the lower than expected revenue relative to our guidance, we achieved non-GAAP EBITDA and non-GAAP EPS within our guided ranges as a result of strong expense management and lower performance-based compensation. At the end of the third quarter of 2022, our cash balance was $266 million, up from $245 million as of June 30, 2022. Cash flow provided by operations was $21 million. Non-GAAP free cash flow during the third quarter of 2022 was $5 million. Our free cash flow in the quarter was impacted by lower cash collections on the reduced revenue and timing of shipments in the quarter. Our accounts receivable days sales outstanding for the third quarter of 2022 was 93 days. The days sales outstanding reflects an increase of 7 days over last quarter, primarily from the timing of invoicing within the quarter. Inventories as of September 30, 2022. For $147 million, a decrease of $3 million from the prior quarter, and an increase of $42 million from the third quarter in 2021. It is important to note that the inventories as of September 30, 2022 include approximately $80 million of advanced purchases and receipts of semiconductors that we believe will help reasonably secure supply for future customer implementation timelines. We believe that we are continuing to execute very well on our global supply chain process improvements and inventory management initiatives. Now moving on to our full year and fourth quarter 2022 guidance. We are revising our full year 2022 outlook due to the following factors. Increased health system CapEx budget freezes, additional healtfull-yearh system capital budget approval processes, which are resulting in elongated sales cycles, health system labor availability impacting implementation schedules, and continued macroeconomic environment uncertainty. Demand for advanced services remains strong, and we're very pleased with the interest in our advanced services portfolio from the top 300 U.S. health systems. However, the factors I noted earlier are impacting our expected full-year bookings, primarily in point of care. As a result, we now expect the following. For full year 2022, we expect product bookings to range between $950 million and $1,050 million. We expect 2022 GAAP and non-GAAP revenues to be between $1.284 billion and $1.294 billion. We expect full year 2022 GAAP and non-GAAP product revenues to range between $889 million and $894 million. We expect full- year 2022 GAAP and non-GAAP service revenues to be between $295 million and $400 million. 340B solutions for 2022 revenue continue to track to our prior estimate of $30-$35 million. We now expect advanced services revenue as a percentage of total revenue to be approximately 14% in 2022. We expect full year 2022 non-GAAP EBITDA to be between $177 million and $183 million, reflecting the margin impact of the reduction in revenue. We expect full year 2022 non-GAAP EPS to be between $2.73 per share and $2.83 per share. We now expect total inflationary costs in 2022 of approximately $30 million. For full year 2022, we are assuming an effective blended tax rate of approximately 6% in our non-GAAP EPS guidance. For the fourth quarter of 2022, we are providing the following guidance. Our outlook incorporates our expectations for the impact of lower revenue as a result of the lower than anticipated bookings at point of care, as well as an uncertain business environment, as I noted previously. We expect total fourth quarter 2022 GAAP and non-GAAP revenues to be between $285 million and $295 million, with GAAP and non-GAAP product revenues to be between $183 million and $188 million, and GAAP and non-GAAP service revenues to be between $102 million and $107 million. We expect fourth quarter 2022 non-GAAP EBITDA to be between $10 million and $60 million, and we expect fourth quarter 2022 non-GAAP earnings per share to be between $0.05 per share and $0.15 per share. In summary, this was a difficult quarter, and we expect the business environment to remain challenging in the near term. We remain confident in our long-term outlook, and we intend to take actions designed to align our cost structure with expected bookings and revenue levels. We are looking at all categories of costs and intend to manage expenses prudently and diligently. At the same time, we plan to continue to invest in our growth agenda. We're committed to delivering value to all of our stakeholders and look forward to updating you on our progress in the coming quarters. With that, we would like to open the call for your questions. At this time, I'd like to remind everyone, in order to ask a question, press star followed by the number one on your telephone keypad. We'll pause for just a moment to compile the Q&A roster. Your first question comes from the line of Stanislav Berenshteyn with Wells Fargo Securities. Your line is open. Hi. Thanks for taking my questions. I guess I'll start with the elephant in the room on the booking side here. You know, it's a pretty sizable reduction this end of the year, but can you walk us through exactly how widespread across your customer base are you seeing these capital budget freezes? Then maybe related to the delay in implementations, have clients provided any visibility into how long they plan to delay these implementations? Yes. Well, I think it's fairly widespread, but not everywhere. I think increasingly more and more large health systems have put a delay, particularly at the end of third quarter when they start to. You know, they started to see their financial results. As far as implementations, we see because there are not enough People on site to deal with the installation process because of labor shortages, and probably also some concern about nursing. These systems all are impacted by nursing as the major user of them, so that they don't want to disrupt the shortage of nursing with another project, have deferred them to when they feel like they have more control over their local environments. Usually, that gets delayed a quarter or two, because they, you know, they've committed to do the upgrade or put the equipment in. That's not going away, but the timing on when it actually happens is the key. Okay. Maybe one quick one. Are you still sticking with your 2025 guidance? No, we are not reaffirming the 2025 framework, but we're remain committed to these targets. We cannot reaffirm the timing at this point. Okay. Thank you. Thanks, Stan Berenshteyn. Next question, please. Your next question is from the line of Jessica Tassan with Piper Sandler. Your line is open. Hi. Thanks for taking the question. I guess just on the 2Q call, you guys specifically said the customers were not delaying, but that if any one of them did, you'd have plenty of backlog to kind of just replace one deployment with another. I guess, what happened with that strategy relative to the products revenue guidance revision? Right? It appeared as if guidance was adequately covered and I guess, where is the disconnect? Hey, Jess, it's Peter. What changed really to the very end of the third quarter was really the timing availability as well. Customer requests of delays of implementations were a multiple of prior quarters. We've seen that multiply. Now that said, the majority of the delays in implementation projects have been rescheduled. Okay. Got it. Just as you talk about kind of pulling back on operating expenses to commensurate with the revenue revision, should we think about the ADC upgrade cycle or upgrade opportunity as being less than that $1.8 billion you outlined a few years back? Two parts to the question there, Jess. We're looking at all types of expenses. Of course, we're looking at variable costs. We'll adjust there accordingly. We'll look at all types of operating expenses as well. As far as the ADC product line, yeah, we do believe that the majority of the upgrade cycle will happen. There is definitely a timing impact. As you can see, the majority of the lowering of the product bookings guidance, the expected product bookings guidance for 2022, the vast majority of that is point of care. Got it. My last quick one is just Walgreens, I think, reported that Shields has partnered with 75 health systems. Curious your view on how many health systems are candidates for their own specialty pharmacy. Can you help us frame the TAM in terms of health systems? Then just I think for Walgreens, at least, this business is growing upwards of 40% a year. Just how quickly do you expect your specialty pharmacy offering to grow? Thanks. Hey, Jess, it's Scott. I think we feel that the specialty pharmacy, the sort of the market for outsourcing the operation of in-house specialty pharmacies is a big market. It's largely greenfield. We think that there is a significant number. The exact counts, I'm not sure quite how to get at, or at least I don't have that at my fingertips. That's something we could follow up on. It's a big greenfield market, and we're well-positioned, and we think that, you know, having this offering paired with Omnicell's channel, but more importantly, our other products and services is a significant differentiator, and we're really excited about the growth. Got it. Your next question is from the line of Allen Lutz with Bank of America. Your line is open. Thanks for taking the questions. I guess one for Peter. Can you talk about the timing of any potential OpEx reductions? Is this something we could see in Q4, or is this more of a 2023 dynamic? Yeah. We're going through the planning, of course, of operating expense and also variable cost actions, and we'll update accordingly. You know, in the next couple of months, we'll provide more clarity on the sizing, the impact, and the timing of the cost actions. Okay. Thank you. Then, as you mentioned, delays began really at the end of third quarter when health systems started to see their financial results. Can you provide any type of context historically when there has been a slowdown or a change in the conversation with these health systems, how long that typically takes to play out? I know that, you know, every cycle is different than the last. Typically, you know, how long does that typically last? Thanks. Yeah. Thanks for the question. I think and this is really unprecedented in my 30 years. Usually, it's a slow ramp down and a slow ramp up, more of a U-shaped when it comes to capital spending in healthcare systems. I really think many of these healthcare systems believe that September was some kind of return to back to normal. They were improving on their margin throughout the year. I think it didn't improve enough. I think with the increased cost of capital, the increased cost of nursing, and the uncertainty of what that cost might be, the availability of labor all impacted sort of at the same time, which created this sort of frozen moment for some of the health systems to have orders in hand that they deferred. I think it's really unprecedented. I think we don't know a lot about the future because this is such an unusual time and you know, precisely how it will come back and when it'll come back. One thing I know, long term, they need the systems. They know that their infrastructure and pharmacy is underinvested in, and so these orders aren't disappearing, they're deferring. Appreciate the color. Thank you. Your next question is from the line of Scott Schoenhaus with KeyBanc. Your line is open. Hi, team. Drilling in on the full-year guidance, you know, everyone's talked about the lower revenue guide coming from the delayed sales cycle and delayed installations that deteriorated rapidly in the quarter. I want to focus on the profitability guidance that came down by 28%. Peter, I guess, can you break out the makeup of this guide down? How much of this was due to the integration cost, and how much of this was due to higher labor costs and slower macro? Thanks. Thank you for the question, Scott. First of all, integration costs are tracking to the original guidance. It's about $6 million-$8 million for the year. That remains on track. Integration by itself is going well also. We're hitting the milestones from an integration perspective. I would say 90% plus of the decrease in profitability on an EBITDA level is driven by the reduction in volume, mostly for product revenue. Thanks. Did you have a follow-up, Scott? No, that's it. Thank you. Thank you. Your next question is from Matt Hewitt with Craig-Hallum Capital Group. Your line is open. Good morning, and thank you for taking the questions. I guess this kind of goes back to a couple of questions ago regarding, you know, this potentially being an unprecedented situation that you're facing. If I think back to 2008 and 2009, when you had the credit freeze, essentially, short-term markets froze up, I feel like at that time you ran into a somewhat similar situation where I'm drawing a blank here. But if I remember correctly, it was like Q4 you provided your fiscal outlook for, I think it was for 2009. By Q1, ordering patterns had changed because the markets had froze, the short-term funding markets. I don't know if you can remember, but how long did it take for those things? I realize it's a little bit different situation in that now you've got labor shortages, but it was still a credit financial situation where the budgets froze. It required extra time to get signatures. Is there any correlation to that period? Yeah. Well, I'm kind of reaching back into my memory bank there. Maybe that was a year I tried to forget, but I'm sure it was probably a year or so before. It didn't fall back all at once. It sort of did a gradual upswing as the credit markets unfroze and people could really see their cash flows. That was more of a financial driven. Well, I guess the cost of capital here is also sort of a factor. I actually think the factor is more about readiness to accept systems with the labor shortage and the sensitivity to nurse activities than just the capital alone. People need the systems. People need to install them and upgrade them. Eventually, the systems that they have, they're not upgraded, have to be upgraded, so that will come. Now they're trying to delay it as, you know, long as they can until they get a firmer grip on their own financial situation. You know, my recalling, I think it's, you know, it was within the year. That's helpful, Randy. Thank you. Then maybe as you look at the current delays, how much of those would you say are tied to budget conditions versus labor? Are there customers that it's simply, "Listen, we've got the money. We want to implement these systems, but we just don't have the staff." Is there something that you could do on your side, even if it's just over the short term, to help get those systems integrated? Thank you. Hi, this is Scott. Honestly, I think the behavior at the hospital side is a bit frenetic. Most of what we're hearing, the vast majority of what we're hearing is, you know, kind of last minute, "Oop. Like, gosh, we don't have the staffing for this. Can we push this out a couple of weeks?" Or, "Oh, gosh, we thought we had staging areas, but we don't have staging area. Can we move it around?" Very, very little of what we've heard has been sort of a financial question or issue driving the delay. It's simply been mostly, "Gosh, I'm down 40 people to begin with, and now I'm down 10 more. I just don't have the staff right now. We have looked at supplementing some of the labor on site to help with some of those situations. There's a limited amount of things that we can do as an outside vendor in some of those situations. You know, we're looking at ways to ease the pain. Understood. Thank you. Thanks, Matt. Your next question is from Dev Weerasinghe with Berenberg Capital Markets. Your line is open. Hey, good morning. Thanks for taking my questions. The first one, just, you know, curious how much of the bookings backlog, the products, the customers that you have for bookings backlog have you had discussions with in regards to these delays? Because what I'm wondering is if there's, you know, more delays from customers that just haven't informed you yet where, you know, part of the product backlog that you currently have, even more will fall off. Any percentage, any color on that would be helpful. I have one more follow-up. Thanks. I don't think we have a percentage. I think that we are expecting that in this environment hospital labor shortages will continue, and that what we're sort of what is included in our guidance in Q4 is the notion that, you know, we will continue to see delays in movement just because hospitals are continuing to struggle. Okay. That's helpful. The other thing is, I guess, you know, kind of around this time, hospitals are also looking into full year 2023 budgets. Curious as to what the discussions are there. You know, as part of these delays, you know, are the discussions that, hey, we expect this to, you know, be implemented in sometime in 2024. I think, Randy mentioned it's usually delayed a couple of quarters. Then from a booking standpoint, you know, with these capital budget freezes, is there any color as to, you know, when that might turn around? Do you expect, you know, for example, the XT replacement upgrades, that to be a windfall in maybe 2023 when, you know, because I don't know how long they could delay that for, right, from an upgrade standpoint. Any color there would be helpful. Thank you. I think to the last point, I think that as Randy pointed out, replacing equipment that is end of life, this falls into the risk management and compliance. That portion of the ADC business, when those need to be replaced, I think we have seen and we believe going forward that hospitals will continue to replace that. That is only a portion of the ADC sales. I think as we think about 2023 and the financial impact to hospitals, and I think my sense is that hospitals are, you know, a bit of what's driving their behavior currently is they're unknown in terms of, you know, when do my electives come back? When does my revenue and my cost model align, et cetera. I think what we're assuming is that this financial challenge for hospitals continues through, you know, 2023. As a result, I think that, you know, we have to think through our bookings through 2023 in a conservative way. All right. Your next question is from the line of Joy Zhang with SVB Securities. Your line is open. Hey, guys. Thanks for taking my question. I want to go back to an earlier question made by one of the analysts, about, you know, this being, you know, questioning why this is sort of unprecedented versus 2008, 2009. I think just looking at the differences, you know, macroeconomically, labor market's much tighter now versus, you know, back then, which should be some sort of offsetting factor to demand, right? Mm-hmm. Looking at your recurring versus non-recurring mix of revenues, you also have a lot more recurring revenues than before. I mean, all these factors point to a sort of slightly better situation versus 2008, 2009. As a follow-up, you know, are there any other factors maybe on the competitive landscape side that could be driving, you know, this situation being, you know, worse than 2008, 2009? Yeah. I would say comparing 2008, 2009 to now, obviously I was talking to the capital equipment point of care market only. Advanced services continue to be strong because of the great ROI and the fact that many of them we provide an expert on site so that they don't actually have to go hire someone to enable some of our solutions to get the optimal output out of them. That really speaks to probably why these services continue to grow through this economic environment situation and labor situation is that's exactly what they need. You know, it's just looking at our financial model, the point of care systems is such a large portion of our growth and our profit right now that as they are affected, until we get through the conversion to the advanced services model more, we're gonna have a bigger impact. Certainly less than it would have been if we were only capital equipment-oriented business as we were then. Certainly a different situation from that standpoint. Appreciate the color. Your next question is from the line of Anne Samuel with J.P. Morgan. Your line is open. Hi. Thanks for taking the question. You know, you've talked in the past about M&A being a big component of your growth strategy. Was just wondering, you know, given some of the pressures that you're facing right now, you know, are there any changes, you know, potentially in the near term to your capital allocation strategy? Well, I think M&A long term is always a key to our strategy. It has been as we transform the business and still will be. I think with that said, you know, we wanna be prudent during this time until we get a really good handle on the pace of the business and the pace of the market. Helpful. Thank you. Your next question is from the line of David Larsen with BTIG. Your line is open. Hi. Can you talk a little bit about what you're seeing in terms of inflation for your costs related to semiconductors, steel, freight? Then can you also talk a little bit about your sourcing for semiconductors? Are they coming from Taiwan or other areas? What are you doing about pricing to help cover these costs for 2023 and beyond? How do you know you're raising prices high enough, and are you getting any pushback from the hospitals? Thanks. Yeah. Thank you for the question. Inflation in our prepared remarks, the inflationary cost headwinds for fiscal 2022 will be brought down by a couple million, about $2-$3 million lower than previously expected. Most of that lower headwind, if you will, for the year is in semiconductors, so we see some favorability there. On your question on the sourcing, it's really a mix of where we get our semiconductors. You can see in the prepared remarks that we have about $18 million by the end of the quarter in pre-purchased and pre-received semis in stock, if you will, to really be certain about being able to supply health systems with our connected devices. We are seeing price increases come through, specifically on in pricing for point of care and also for the robotic equipment. In bookings first, backlog, and then into revenue increasingly. With the $18 million in higher inventory, like, do you have enough semiconductor supply right now to bring you through all of 2023? I think you also mentioned that some of these implementations have been rescheduled. Have they all been rescheduled? Do they all have start dates, or is it just sort of a ambiguous kind of delay there? Thanks. Yeah. On the inventory level and kind of the months of run rate, you know, that is not the full year for calendar 2023, but certainly a good portion of that. As far as the scheduling, I think Scott commented on it as well. We see you know, really the schedule changes or requested changes both from a labor constraint perspective at the health system. We see that continuing, so there's more changes, if you will. By and large, you know, the backlog has a scheduled starting date. Now, the nuance here is that compared to other quarters or other time frames, the frequency and the amount of requested changes of start date of an implementation, that has really been increasing probably 2x-3x on what we normally have seen. It's a continuous process where we refine the scheduling with customers. David, this is Scott. I'd only add there that we see movement every quarter. Yeah. That's not uncommon. Exactly. It's a, you know, relatively modest percentage of the revenue in a quarter that moves around. What's different right now is that we always manage that because of the backlog. If a customer needs to move something out, if we need to move something out, there's plenty to move around and to pull in to cover. What's more challenging in this environment is that the movements now are from customers due to labor constraints. The challenge is that all customers are dealing with that. They're much less fungible to say, "Oh, we'll call the next customer and say, 'Hey, we've got an open slot on Wednesday. Do you wanna get going?'" The customers are just, they're struggling. They don't have that much flexibility. That's the challenge right now which is different. Okay, thanks very much. It sounds like nothing has actually been canceled, where they're saying, "We're canceling this altogether." It's more delayed. Okay. Thanks very much. That's correct. Yeah. Your next question is from Scott Schoenhaus with KeyBanc. Your line is open. Hey, guys. Thanks for the follow-up. Just wanted to circle back on what's different from the previous cycle in the 2008, 2009 recession. Peter, I believe you've always said that you have about 30%-40% of your customer base that uses some part of third-party financing now. That was nothing back in the 2008, 2009 recession. Are you seeing any differences in customer behavior on the ordering side because of that? Then the second question is, I think you automated a lot of your implementation throughout the pandemic as a result of everything being shut down. How much is that helping you now in this tight labor market? Thanks. Yeah, we would say the percentage of our customers in our large customer population using third-party financing is probably still the same around that 40%. That said, though, of course, cost of capital has increased, so we maybe see a little bit of a slowdown there, but the percentage is probably the same. As far as the implementation efficiencies, yeah, we believe that the way we schedule implementation from our perspective, we're definitely more efficient, but we're dependent on timelines or scheduling like Scott pointed out and the customers, right? Your final question comes from the line of Stan Berenshteyn with Wells Fargo Securities. Your line is open. Hi. Thanks for the follow-up. Just quickly on bookings guidance, can you maybe give us some insight into the what part of the bookings mix is coming from long-term bookings? Thank you. Yeah. We lowered the midpoint of the product bookings range by $400 million. The expected bookings for advanced services for the year are on plan essentially. The full reduction is in non-advanced services. The advanced services part, of course, is multi-year. We expect then, you know, consequently the percentage of long term in the mix to go up as well. Stan, or said another way, I'd just add to that is that what we've seen an elongation of sales cycles across the board. The majority of the slowdown is on the point of care side of things. Exactly. Thank you. There are no further questions at this time. It is now my pleasure to turn the call back over to Mr. Randall Lipps. Thank you for joining us on the call today. To our shareholders, we will realign this business to meet with the current economic factors. We are committed to our strategy of moving to advanced services. We're committed to our customers to improve their experience and get better results. We're committed to our employees who will help us get through this difficult time as we emerge and move forward. Thank you for joining us today. Ladies and gentlemen, thank you for participating. This concludes today's conference call. You may now disconnect.